Quantifying the effect of IV contrast media on integrated PET/CT: Clinical evaluation

American Journal of Roentgenology

Volumn 186, Issue 2, 2006, Pages 308-319

  Mawlawi, Osama ^a   Erasmus, Jeremy J ^a   Munden, Reginald F ^a   Pan, Tinsu ^a   Knight, Amy E ^a   Macapinlac, Homer A ^a   Podoloff, Donald A ^a   Chasen, Marvin ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Artifact; Attenuation; Contrast media; PET CT

Indexed keywords

CONTRAST MEDIUM; FLUORODEOXYGLUCOSE F 18; IOVERSOL; IODOBENZOIC ACID DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; ATTENUATION CORRECTION; CANCER LOCALIZATION; CLINICAL ARTICLE; CLINICAL EVALUATION; COMPUTER ASSISTED DIAGNOSIS; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; ESOPHAGUS CANCER; FEMALE; HEART; HUMAN; IMAGE ENHANCEMENT; IMAGE RECONSTRUCTION; LIVER; LUNG NODULE; LUNG NON SMALL CELL CANCER; MALE; PARAMETER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REGION OF INTEREST; SPLEEN; STANDARDIZED UPTAKE VALUE; SUBCLAVIAN VEIN; THORAX CANCER; CANCER STAGING; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ESOPHAGUS TUMOR; INTRAVENOUS DRUG ADMINISTRATION; LUNG TUMOR; MIDDLE AGED; RADIOGRAPHY; SCINTISCANNING;

CONTRAST MEDIA; ESOPHAGEAL NEOPLASMS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INJECTIONS, INTRAVENOUS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOPHARMACEUTICALS; SUBCLAVIAN VEIN; TOMOGRAPHY, EMISSION-COMPUTED; TOMOGRAPHY, X-RAY COMPUTED; TRIIODOBENZOIC ACIDS;

EID: 33644978708     PISSN: 0361803X     EISSN: None     Source Type: Journal    
DOI: 10.2214/AJR.04.1740     Document Type: Article

References (38)

1. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual-modality PET/CT in preoperative staging. Radiology 2003; 229:526-533
2. Cohade C, Wahl RL. Applications of positron emission tomography/computed tomography image fusion in clinical positron emission tomography: clinical use, interpretation methods, diagnostic improvements. Semin Nucl Med 2003; 33:228-237
3. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348:2500-2507
4. Langen KJ, Braun U, Rota Kops E, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34:355-359
5. Burgener FA, Hamlin DJ. Contrast enhancement of focal hepatic lesions in CT: effect of size and histology. AJR 1983; 140:297-301
6. Garrett PR, Meshkov SL, Perlmutter GS. Oral contrast agents in CT of the abdomen. Radiology 1984; 153:545-546
7. Antoch G, Freudenberg LS, Egelhof T, et al. Focal tracer uptake: a potential artifact in contrast-enhanced dual-modality PET/CT scans. J Nucl Med 2002; 43:1339-1342
8. Nakamoto Y, Chin BB, Kraitchman DL, Lawler LP, Marshall LT, Wahl RL. Effects of nonionic intravenous contrast agents at PET/CT imaging: phantom and canine studies. Radiology 2003; 227:817-824
9. Kinahan PE, Townsend DW, Beyer T, Sashin D. Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998; 25:2046-2053
10. Mawlawi O, Kohlmyer S, Williams JJ, et al. Performance characteristics of the GE Discovery ST PET/CT scanner using the NEMA standard. (abstr) J Nucl Med 2003; 44:111
11. Stearns CW, Fessier JA. 3D PET reconstruction with FORE and WLS-OS-EM. Proceedings of the IEEE Nuclear Science Symposium. Norfolk, VA: Institute of Electrical and Electronics Engineers, 2002:912-915
12. Padilla J, Calvo V, Penalver JC, Sales G, Morcillo A. Surgical results and prognostic factors in early non-small cell lung cancer. Ann Thorac Surg 1997; 63:324-326
13. Pelosi E, Messa C, Sironi S, et al. Value of integrated PET/CT for lesion localisation in cancer patients: a comparative study. Eur J Nucl Med Mol Imaging 2004; 31:932-939
14. Antoch G, Freudenberg LS, Stattaus J, et al. Whole-body positron emission tomography-CT: optimized CT using oral and IV contrast materials. AJR 2002; 179:1555-1560
15. Kluetz PG, Meltzer CC, Villemagne VL, et al. Combined PET/CT imaging in oncology: impact on patient management. Clin Positron Imaging 2000; 3:223-230
16. Messa C, Bettinardi V, Picchio M, et al. PET/CT in diagnostic oncology. Q J Nucl Med Mol Imaging 2004; 48:66-75
17. Cook GJ, Wegner EA, Fogelman I. Pitfalls and artifacts in 18FDG PET and PET/CT oncologic imaging. Semin Nucl Med 2004; 34:122-133
18. Townsend DW, Carney JP, Yap JT, Hall NC. PET/CT today and tomorrow. J Nucl Med 2004; 45[suppl 1]:4S-14S
19. Kroep JR, Van Groeningen CJ, Cuesta MA, et al. Positron emission tomography using 2-deoxy-2-[18F]-fluoro-D-glucose for response monitoring in locally advanced gastroesophageal cancer; a comparison of different analytical methods. Mol Imaging Biol 2003; 5:337-346
20. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21:2651-2657
21. van der Hiel B, Pauwels EK, Stokkel MP. Positron emission tomography with 2-[18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa: Therapy response monitoring in breast cancer, lymphoma and gliomas. J Cancer Res Clin Oncol 2001; 127:269-277
22. Weber WA, Ott K, Becker K, et al. Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging. J Clin Oncol 2001; 19:3058-3065
23. Stahl A, Ott K, Schwaiger M, Weber WA. Comparison of different SUV-based methods for monitoring cytotoxic therapy with FDG PET. Eur J Nucl Med Mol Imaging 2004; 31:1471-1478
24. De Santis M, Becherer A, Bokemeyer C, et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: an update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22:1034-1039
25. Grigsby PW, Siegel BA, Dehdashti F, Rader J, Zoberi I. Posttherapy [18F] fluorodeoxyglucose positron emission tomography in carcinoma of the cervix: response and outcome. J Clin Oncol 2004; 22:2167-2171
26. Ott K, Fink U, Becker K, et al. Prediction of response to preoperative chemotherapy in gastric carcinoma by metabolic imaging: results of a prospective trial. J Clin Oncol 2003; 21:4604-4610
27. Mac Manus MP, Hicks RJ, Matthews JP, et al. Positron emission tomography is superior to computed tomography scanning for response-assessment after radical radiotherapy or chemoradiotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2003; 21:1285-1292
28. Spaepen K, Stroobants S, Dupont P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? J Clin Oncol 2001; 19:414-419
29. Gennari A, Donati S, Salvadori B, et al. Role of 2-[18F]- fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients. Clin Breast Cancer 2000; 1:156-161; discussion, 162-163
30. Zinzani PL, Fanti S, Battista G, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91:850-354
31. Port JL, Kent MS, Korst RJ, Keresztes R, Levin MA, Altorki NK. Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer. Ann Thorac Surg 2004; 77:254-259; discussion, 259
32. Wahl RL, Zasadny K, Helvie M, Hutchins GD, Weber B, Cody R. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111
33. Smith TA. FDG uptake, tumour characteristics and response to therapy: a review. Nucl Med Commun 1998; 19:97-105
34. Young H, Baum R, Cremerius U, et al. Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35:1773-1782
35. Visvikis D, Costa DC, Croasdale I, et al. CT-based attenuation correction in the calculation of semi-quantitative indices of [18F]FDG uptake in PET. Eur J Nucl Med Mol Imaging 2003; 30:344-353
36. Schoder H, Erdi YE, Chao K, Gonen M, Larson SM, Yeung HW. Clinical implications of different image reconstruction parameters for interpretation of whole-body PET studies in cancer patients. J Nucl Med 2004; 45:559-566
37. Graham J, Bradley YC, Smith R. Does the use of intravenous contrast on a PET/CT affect the PET SUV data? (abstr) The Radiological Society of North America, 90th Scientific Assembly and Annual Meeting. Chicago, IL: The Radiological Society of North America, 2004: 371
38. Antoch G, Freudenberg LS, Beyer T, Bockisch A, Debatin JF. To enhance or not to enhance? 18F-FDG and CT contrast agents in dual-modality 18F-FDG PET/CT. J Nucl Med 2004; 45[suppl 1]:56S-65S